In November, the FDA cleared UCB’s Bimzelx for hidradenitis suppurativa, Emrosi capsule for rosacea, and Danziten, the first nilotinib medicine without mealtime restrictions. Aucatzyl is cleared for ALL, an aggressive blood cancer, and Kebilidi is a gene replacement therapy administered directly into the brain. Additional approvals are first-in-class oral Revuforj for leukemia, Ziihera for biliary tract cancer, Attruby for cardiomyopathy, an oral imatinib solution called Imkeldi and Rapiblyk to treat an abnormally rapid heart rate.